Neuroscientific Biopharmaceuticals Ltd. (AU:NSB)
ASX:NSB
Top Page
Neuroscientific Biopharmaceuticals Ltd.
(Sydney:NSB)
Select Model
Select Model
Rating:42Neutral
Price Target:
AU$0.07
▼(-28.00% Downside)
Action:UpgradedDate:03/27/26
The score is held down primarily by weak financial performance (revenue collapse, recurring losses, and cash burn) and bearish technical positioning (trading below all major moving averages with negative MACD). Valuation is also a negative factor due to losses (negative P/E) and no indicated dividend support, partially offset by the low financial leverage (no reported debt).
Positive Factors
Zero reported debt
Zero reported debt materially reduces fixed financing costs and balance-sheet vulnerability for a small biotech. Over the next 2–6 months this lowers default and interest-rate risk, preserves flexibility to fund trials or partnerships, and makes equity or non-debt financing options more feasible.
Negative Factors
Revenue collapsed to zero (2025)
A full-year revenue collapse erodes operational resilience and the firm’s ability to self-fund development. Over several months this removes a recurring cash inflow, increases dependency on external capital, and reduces visibility on commercialization prospects and partner interest.
Read all positive and negative factors
Positive Factors
Negative Factors
Zero reported debt
Zero reported debt materially reduces fixed financing costs and balance-sheet vulnerability for a small biotech. Over the next 2–6 months this lowers default and interest-rate risk, preserves flexibility to fund trials or partnerships, and makes equity or non-debt financing options more feasible.
Read all positive factors
Neuroscientific Biopharmaceuticals Ltd. (NSB) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$23.61M
Dividend YieldN/A
Average Volume (3M)306.60K
Price to Earnings (P/E)―
Beta (1Y)0.68
Revenue GrowthN/A
EPS Growth-672.73%
CountryAU
EmployeesN/A
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding332,575,700
10 Day Avg. Volume291,172
30 Day Avg. Volume306,603
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.76
Price to Sales (P/S)0.00
P/FCF Ratio-13.54
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Neuroscientific Biopharmaceuticals Ltd. Business Overview & Revenue Model
Company Description
NeuroScientific Biopharmaceuticals Limited develops therapeutic treatments for neurodegenerative diseases through preclinical and clinical studies of patented technologies. Its lead drug candidates include EmtinB for treatment of neurodegenerative...
How the Company Makes Money
null...
Neuroscientific Biopharmaceuticals Ltd. Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
67
Positive
Cash Flow
18
Very Negative
| Breakdown | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 2.21M | 4.95M | 0.00 | 958.77K |
| Gross Profit | -92.78K | -91.34K | -57.85K | -64.92K | 897.36K |
| EBITDA | -1.92M | -1.80M | -5.96M | -10.37M | -3.12M |
| Net Income | -1.85M | 324.21K | -1.07M | -10.44M | -3.18M |
Balance Sheet | |||||
| Total Assets | 16.96M | 5.44M | 5.29M | 7.74M | 14.83M |
| Cash, Cash Equivalents and Short-Term Investments | 7.27M | 4.95M | 4.91M | 7.22M | 14.16M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 149.22K | 85.68K | 597.36K | 2.22M | 223.41K |
| Stockholders Equity | 16.81M | 5.35M | 4.69M | 5.52M | 14.60M |
Cash Flow | |||||
| Free Cash Flow | -941.33K | 42.43K | -2.30M | -6.95M | -2.63M |
| Operating Cash Flow | -941.33K | 44.25K | -2.30M | -6.94M | -2.60M |
| Investing Cash Flow | -36.04K | -1.81K | 0.00 | -3.87K | -29.88K |
| Financing Cash Flow | 3.29M | 0.00 | 0.00 | 0.00 | 13.51M |
Neuroscientific Biopharmaceuticals Ltd. Technical Analysis
Negative
0.10
Price Trends
0.12
Negative
0.12
Negative
0.14
Negative
Market Momentum
>-0.01
Positive
32.12
Neutral
30.99
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:NSB, the sentiment is Negative. The current price of 0.1 is above the 20-day moving average (MA) of 0.09, below the 50-day MA of 0.12, and below the 200-day MA of 0.14, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 32.12 is Neutral, neither overbought nor oversold. The STOCH value of 30.99 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:NSB.
Neuroscientific Biopharmaceuticals Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | AU$71.24M | -7.57 | -179.37% | ― | ― | 16.61% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | AU$197.36M | 27.58 | -15.96% | ― | -40.74% | -21.21% | |
43 Neutral | AU$109.32M | -5.66 | -100.58% | ― | ― | 26.38% | |
42 Neutral | AU$23.61M | -5.38 | -19.10% | ― | ― | -672.73% | |
42 Neutral | AU$55.73M | -5.28 | -62.49% | ― | ― | 10.78% | |
40 Underperform | AU$35.68M | -10.60 | -142.30% | ― | 110.44% | 35.90% |
* Healthcare Sector Average
AU:NSB
Neuroscientific Biopharmaceuticals Ltd.
0.07
0.03
77.50%
AU:CYP
Cynata Therapeutics Limited
0.30
0.11
62.16%
AU:PTX
Prescient Therapeutics Limited
0.05
<0.01
12.77%
AU:SPL
Starpharma Holdings Limited
0.47
0.38
400.00%
AU:ILA
Island Pharmaceuticals Ltd
0.37
0.21
124.24%
AU:ADO
AnteoTech Ltd
0.01
0.00
0.00%
Neuroscientific Biopharmaceuticals Ltd. Corporate Events
NeuroScientific scales up StemSmart manufacturing with Q-Gen for Phase 2 trials
Mar 16, 2026
NeuroScientific Biopharmaceuticals has started the first technology transfer manufacturing run for its StemSmart mesenchymal stem cell therapy at Q-Gen Cell Therapeutics in Brisbane. The move shifts StemSmart’s patented manufacturing process...
NeuroScientific Revenue Surges but Half-Year Loss Deepens and Asset Base Shrinks
Feb 25, 2026
NeuroScientific Biopharmaceuticals Limited reported its Appendix 4D results for the half-year ended 31 December 2025, highlighting a 359% increase in revenue from ordinary activities to $436,301 compared with the prior corresponding period. Despit...
NeuroScientific Advances StemSmart™ Program as Crohn’s Trial Prep Gathers Pace
Jan 29, 2026
NeuroScientific Biopharmaceuticals has advanced clinical and operational development of its StemSmart™ mesenchymal stem cell platform during the December 2025 quarter, with a particular focus on treating patients with severe, treatment-resis...
NeuroScientific’s StemSmart Therapy Delivers Strong Results in Fistulising Crohn’s Patients
Jan 12, 2026
NeuroScientific Biopharmaceuticals reported that three of four patients with fistulising Crohn’s disease treated with its patented StemSmart™ mesenchymal stem cell therapy under Australia’s Special Access Scheme achieved a succes...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.